Middle East & Africa Prostate Cancer Market Research Report - Segmented By Diagnostic Techniques, Surgery, Radiation Therapy, Chemotherapy and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: June, 2024
ID: 1541
Pages: 135

MEA Prostate Cancer Market Size (2023 to 2028)

The prostate cancer market size in the Middle East & Africa is estimated to grow from USD 5.5 billion in 2023 to USD 8.61 billion by 2028, growing at a CAGR of 9.38% from 2023 to 2028.

Prostate cancer is the abnormal and uncontrolled growth of cells in the prostate gland of a male individual. The majority of prostate cancers are developed sporadically in which genetic changes occur after birth. Although the cause of prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight and past history of certain cancers. In addition, a person with cardiovascular disease is more prone to advanced metastatic cancer.

Promising drug pipelines, developing treatment patterns, rising untapped non-metastatic prostate cancer space, and increased patient awareness are the factors that are expected to enhance the market growth. In addition, improved government funding for cancer and growing awareness about prostate cancer would be one of prime reasons for the unparalleled market growth.

Stringent regulations are restraining the growth of the prostate cancer market in the MEA region.

This research report on the Middle East and Africa prostate cancer market has been segmented and sub-segmented into the following categories.

By Diagnostic Techniques: 

  • Digital Rectal Exam (DRE)
  • Prostate-Specific Antigen Test (PSA)

By Surgery: 

  • Radical Prostatectomy
  • Orchidectomy
  • Trans Urethral Resection (TUR)

By Radiation Therapy: 

  • External Beam Radiation Therapy
  • Brachytherapy

By Chemotherapy: 

  • Docetaxel
  • Etoposide
  • Vinblastine
  • Carboplatin
  • Vinorelbine

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the South African prostate cancer market is predicted to account for the largest share among others in the MEA region during the forecast period, owing to a growing focus on prostate cancer diagnostics products and increased awareness of the disease. In addition, prostate cancer growth is closely linked to age, and with the growing geriatric population, there is a significant increase in prostate cancer incidence. This is projected to drive the prostate cancer diagnostics market by increasing the demand for diagnostics products to detect the condition.

During the forecast period, technological developments in diagnostic tests are expected to boost MEA market expansion further. According to the National Cancer Institute, researchers are now studying the use of artificial intelligence to identify prostate cancer. During a Magnetic Resonance Imaging scan, AI technologies identify problem spots that require biopsies to validate the diagnosis. It is the second leading cause of cancer morbidity and mortality among Ethiopian men. Despite a few studies on the disease burden, evidence on prostate cancer patients' survival and prognostic variables in Ethiopia is limited. As a result, the survival and predictive variables of individuals with prostate cancer were explored in this research. With the increase in new market players aiming to enter into the business through distribution agreements and investing in prostate cancer diagnosis, the sector is expected to expand, creating an opportunity for the prostate cancer diagnostics market.

KEY MARKET PLAYERS:

Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech are some of the notable companies in the MEA prostate cancer market.

Please wait. . . . Your request is being processed

Anil Kumar P is research manager at Market Data Forecast and responsible for Healthcare Domain.

Author

Anil Kumar P (Research Manager - Healthcare)

Anil Kumar P is the lead author of this report and the manager of the team responsible for authoring healthcare reports at Market Data Forecast. He holds a Bachelor’s degree in Pharmacy (Hons.) from BITS Pilani, one of India’s premier institutions. Over the past seven years, Anil has gained extensive experience working with multiple market research companies, where he has collaborated with a diverse range of clients—from innovative startups to Fortune 500 companies—delivering data-driven insights and strategic advice that drive business growth.

Read More

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample